Viridian Therapeutics discovers and develops innovative microRNA-targeting therapies to improve human health.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 4, 2022 | Post-IPO Debt | $75M | 1 | Hercules Capital | — | Detail |
Jun 3, 2009 | Series A | $4M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |
The Peierls Foundation | — | Series A |